Literature DB >> 28523493

The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Renata de S B Fróes1,2, Ana Teresa Pugas Carvalho1, Antonio Jose de V Carneiro3, Adriana Maria Hilu de Barros Moreira2, Jessica P L Moreira4, Ronir R Luiz4, Heitor S de Souza5,6.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) might have economic and social impacts in Brazil, where its prevalence has increased recently. This study aimed to assess disability due to IBD in the Brazilian population and demographic factors potentially associated with absence from work.
METHODS: Analysis was performed using the computerized Single System of Social Security Benefits Information, with a cross-check for aid pension and disability retirement, for Crohn's disease (CD) and ulcerative colitis (UC). Additional data were obtained from the platform, including the average values, benefit duration, age, gender and region of the country.
RESULTS: Temporary disability occurred more frequently with UC, whereas permanent disability was more frequent with CD. Temporary disability affected more younger patients with CD than patients with UC. Temporary work absences due to UC and CD were greater in the South, and the lowest absence rates due to CD were noted in the North and Northeast. Absence from work was longer (extending for nearly a year) in patients with CD compared to those with UC. The rates of temporary and permanent disability were greater among women. Permanent disability rates were higher in the South (UC) and Southeast (CD). The value of benefits paid for IBD represented approximately 1% of all social security benefits. The benefits paid for CD were higher than for UC, whereas both tended to decrease from 2010 to 2014.
CONCLUSIONS: In Brazil, IBD frequently causes disability for prolonged periods and contributes to early retirement. Reduction trends may reflect improvements in access to health care and medication. Vocational rehabilitation programs may positively impact social security and the patients' quality of life.

Entities:  

Keywords:  Crohn’s disease; Indirect costs; Inflammatory bowel diseases; Productivity loss; Ulcerative colitis; Work disability

Mesh:

Year:  2017        PMID: 28523493     DOI: 10.1007/s10198-017-0896-4

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  37 in total

Review 1.  Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

Authors:  Paweł Kawalec; Krzysztof Piotr Malinowski
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-02-06       Impact factor: 2.217

2.  Cost of breast cancer in Sweden in 2002.

Authors:  Mathias Lidgren; Nils Wilking; Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2007-03

3.  Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease.

Authors:  Henrik Stjernman; Curt Tysk; Sven Almer; Magnus Ström; Henrik Hjortswang
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 2.566

4.  [Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].

Authors:  Margrit Rösch; Reiner Leidl; Stefanie Thomas; Christian von Tirpitz; Max Reinshagen; Guido Adler; Hans-Helmut König
Journal:  Med Klin (Munich)       Date:  2002-03-15

5.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

6.  Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Authors:  Uwe Siebert; Johannes Wurm; Raffaella Matteucci Gothe; Marjan Arvandi; Stephan R Vavricka; Roland von Känel; Stefan Begré; Michael C Sulz; Christa Meyenberger; Markus Sagmeister
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

7.  The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey.

Authors:  Michael L Ganz; Rebecca Sugarman; Rosa Wang; Brian Bekker Hansen; Jonas Håkan-Bloch
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

8.  Inflammatory bowel disease: a patient's and caregiver's perspective.

Authors:  F Magro; F Portela; P Lago; J Deus; J Cotter; I Cremers; A Vieira; P Peixe; P Caldeira; H Lopes; R Gonçalves; J Reis; M Cravo; L Barros; P Ministro; M Lurdes Tavares; A Duarte; M Campos; L Carvalho
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

9.  Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: a chart review analysis.

Authors:  Keith Bodger; Linnette Yen; Agota Szende; Gunjan Sharma; Yaozhu J Chen; John McDermott; Paul Hodgkins
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-02       Impact factor: 2.566

Review 10.  Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome.

Authors:  Dan Knights; Kara G Lassen; Ramnik J Xavier
Journal:  Gut       Date:  2013-10       Impact factor: 23.059

View more
  7 in total

1.  Evaluation of Home Polysomnography Findings, Quality of Sleep, and Fatigue in Inflammatory Bowel Disease: A Case Series.

Authors:  Deise Lun Paixão; Dalva Poyares; Marta Sevilh de Paula; Joselmo Willamy Duarte; Paula Midor Castelo; Orlando Ambrogini-Júnior; Sender Jankie Miszputen; Celina Tizuko Fujiyam Oshima; Jair Ribeir Chagas; Ana Paula Ribeir Paiotti
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

2.  Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction.

Authors:  Youlian Zhou; Zhenjiang Zech Xu; Yan He; Yunsheng Yang; Le Liu; Qianyun Lin; Yuqiang Nie; Mingsong Li; Fachao Zhi; Side Liu; Amnon Amir; Antonio González; Anupriya Tripathi; Minhu Chen; Gary D Wu; Rob Knight; Hongwei Zhou; Ye Chen
Journal:  mSystems       Date:  2018-01-30       Impact factor: 6.496

3.  Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management - a follow-up study in a private inflammatory bowel disease center (2003-2017).

Authors:  D B Cury; R Oliveira; M S Cury
Journal:  J Inflamm Res       Date:  2019-05-28

4.  Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.

Authors:  Rogerio S Parra; Julio M F Chebli; Heda M B S Amarante; Cristina Flores; Jose M L Parente; Odery Ramos; Milene Fernandes; Jose J R Rocha; Marley R Feitosa; Omar Feres; Antonio S Scotton; Rodrigo B Nones; Murilo M Lima; Cyrla Zaltman; Carolina D Goncalves; Isabella M Guimaraes; Genoile O Santana; Ligia Y Sassaki; Rogerio S Hossne; Mauro Bafutto; Roberto L K Junior; Mikaell A G Faria; Sender J Miszputen; Tarcia N F Gomes; Wilson R Catapani; Anderson A Faria; Stella C S Souza; Rosana F Caratin; Juliana T Senra; Maria L A Ferrari
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

5.  Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil.

Authors:  Tarcia Nogueira Ferreira Gomes; Fabio Silva de Azevedo; Marjorie Argollo; Sender Jankiel Miszputen; Orlando Ambrogini
Journal:  Clin Exp Gastroenterol       Date:  2021-03-17

6.  Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.

Authors:  Padhmanand Sudhakar; Dahham Alsoud; Judith Wellens; Sare Verstockt; Kaline Arnauts; Bram Verstockt; Severine Vermeire
Journal:  J Crohns Colitis       Date:  2022-08-30       Impact factor: 10.020

7.  Hospitalizations and in-hospital mortality for inflammatory bowel disease in Brazil.

Authors:  Ana Luiza Vilar Guedes; Amanda Lopes Lorentz; Larissa Fernandes de Almeida Rios Rios; Beatriz Camara Freitas; Adriano Gutemberg Neves Dias; Ana Luísa Eckhard Uhlein; Felipe Oliveira Vieira Neto; Jobson Felipe Soares Jesus; Túlio de Sá Novaes Torres; Raquel Rocha; Vitor D Andrade; Genoile Oliveira Santana
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-01-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.